Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-05-2022 | Hepatocellular Carcinoma | Original Article – Clinical Oncology

The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals

Authors: Rixiong Wang, Nan Lin, Binbin Mao, Qing Wu

Published in: Journal of Cancer Research and Clinical Oncology | Issue 5/2022

Abstract

Background

This study was designed to investigate the efficacy and safety of immune checkpoint inhibitors (ICIs) in advanced hepatocellular carcinoma (HCC).

Methods

Electronic databases were scanned to identify relevant trials. The primary endpoints were overall survival (OS), progression-free survival (PFS), and their prognostic factors. Stratified analyses were accomplished on ICIs agent and evaluation criteria.

Results

Totally, 3697 individuals from 40 cohorts were recruited. For patients treated with ICIs, the pooled median time to progression (TTP) was 8.0 months, median PFS 4.9 months, and median OS 12.0 months; the pooled median PFS and OS of ICIs plus anti-vascular endothelial growth factor (VEGF) agents (PFS: 6.3 months, OS: 16.4 months) were longer than those of ICIs alone. Furthermore, Child–Pugh stage (HR = 1.37, P = 0.0123) and Eastern Cooperative Oncology Group (ECOG) (HR = 1.40, P = 0.0016) were prognostic factors for PFS. Hepatitis C virus (HCV) (HR = 0.71, P = 0.0356), Alpha-fetoprotein (AFP) (HR = 1.17, P < 0.0001), Child–Pugh stage (HR = 1.58, P < 0.0001), Barcelona Clinic Liver Cancer (BCLC) stage (HR = 1.23, P = 0.0005), ECOG (HR = 1.50, P = 0.0012), portal vein invasion (HR = 1.32, P = 0.0053), extrahepatic metastasis (HR = 0.84, P = 0.0047), best response (HR = 0.58, P < 0.0001), and neutrophil-to-lymphocyte ratio (NLR) (HR = 1.23, P = 0.0451) were the prognostic factors for OS. According to both RECIST 1.1 and mRECIST, the objective response rate (ORR) and disease control rate (DCR) rate of ICIs plus anti-VEGF agents were better than those of ICIs alone. The overall rate of any grade adverse events (AEs) was 0.76 (95% CI 0.61–0.89), grade 3 or higher AEs was 0.28 (95% CI 0.15–0.42), and the rate of AEs leading to treatment discontinuation was 0.09 (95% CI 0.06–0.12).

Conclusions

The ICIs was promising in HCC with good efficacy and tolerated toxicity. Compared with ICIs monotherapy, the joint application of ICIs and anti-VEGF agents can contribute a lot more benefits to the survival of patients according to clinical practices.

Available only for authorised users

Bagley SJ, Kothari S, Aggarwal C et al (2017) Pretreatment neutrophilto-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer 106:1–7. https://doi.org/10.1016/j.lungcan.2017.01.013CrossRefPubMed

Bomze D, Meirson T, Azoulay D (2020) Atezolizumab and bevacizumab in hepatocellular carcinoma. N Engl J Med 383(7):693–694. https://doi.org/10.1056/NEJMc2021840CrossRefPubMed

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492CrossRefPubMed

Bruix J, Qin S, Merle P et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389(10064):56–66. https://doi.org/10.1016/S0140-6736(16)32453-9CrossRefPubMed

Cheng H, Luo G, Lu Y et al (2016) The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients. Pancreatology 16(6):1080–1084. https://doi.org/10.1016/j.pan.2016.09.007CrossRefPubMed

Cheng AL, Hsu C, Chan SL, Choo SP, Kudo M (2020) Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol 72(2):307–319. https://doi.org/10.1016/j.jhep.2019.09.025CrossRefPubMed

Choi C, Yoo GS, Cho WK, Park HC (2019) Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma. World J Gastroenterol 25(20):2416–2429. https://doi.org/10.3748/wjg.v25.i20.2416CrossRefPubMedPubMedCentral

El-Khoueiry AB, Sangro B, Yau T et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389(10088):2492–2502. https://doi.org/10.1016/S0140-6736(17)31046-2CrossRefPubMedPubMedCentral

El-Serag HB, Marrero JA, Rudolph L, Reddy KR (2008) Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134:1752–1763. https://doi.org/10.1053/j.gastro.2008.02.090CrossRefPubMed

Finn RS, Qin S, Ikeda M et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382(20):1894–1905. https://doi.org/10.1056/NEJMoa1915745CrossRefPubMed

Fouad YA, Aanei C (2017) Revisiting the hallmarks of cancer. Am J Cancer Res 7(5):1016–1036PubMedPubMedCentral

Fukuda R, Sugawara S, Kondo Y (2020) Immune checkpoint inhibitor can reduce HCV-RNA without liver damage. Intern Med 59(18):2245–2248. https://doi.org/10.2169/internalmedicine.3726-19CrossRefPubMedPubMedCentral

Furuse J (2008) Sorafenib for the treatment of unresectable hepatocellular carcinoma. Biologics 2(4):779–788PubMedPubMedCentral

Gibney GT, Weiner LM, Atkins MB (2016) Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol 17(12):e542–e551. https://doi.org/10.1016/S1470-2045(16)30406-5CrossRefPubMedPubMedCentral

Gomaa AI, Waked I (2015) Recent advances in multidisciplinary management of hepatocellular carcinoma. World J Hepatol 7(4):673–687. https://doi.org/10.4254/wjh.v7.i4.673CrossRefPubMedPubMedCentral

Gonda K, Shibata M, Kanke Y, Yazawa T, Takenoshita S (2013) Circulating myeloid-derived suppressor cells (MDSC) and correlation to poor prognosis, Th2- polarization, inflammation, and nutritional damages in patients with gastric cancer. J Clin Oncol 31(15 Suppl):3063CrossRef

Jonsson L, Andreasen N, Kilander L et al (2006) Patient-and proxy-reported utility in Alzheimer disease using the EuroQoL. Alzheimer Dis Assoc Disord 20:49–55. https://doi.org/10.1097/01.wad.0000201851.52707.c9CrossRefPubMed

Kudo M, Finn RS, Qin S et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391(10126):1163–1173. https://doi.org/10.1016/S0140-6736(18)30207-1CrossRefPubMed

Kuo HY, Chiang NJ, Chuang CH et al (2020) Impact of immune checkpoint inhibitors with or without a combination of tyrosine kinase inhibitors on organ-specific efficacy and macrovascular invasion in advanced hepatocellular carcinoma. Oncol Res Treat 43(5):211–220. https://doi.org/10.1159/000505933CrossRefPubMed

Lee MS, Ryoo BY, Hsu CH et al (2020) Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol 21(6):808–820. https://doi.org/10.1016/S1470-2045(20)30156-XCrossRefPubMed

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Vlierberghe HV (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390. https://doi.org/10.1056/NEJMoa0708857CrossRefPubMed

Llovet JM, Montal R, Sia D, Finn RS (2018) Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol 15(10):599–616. https://doi.org/10.1038/s41571-018-0073-4CrossRefPubMed

Moses K, Brandau S (2016) Human neutrophils: their role in cancer and relation to myeloid-derived suppressor cells. Semin Immunol 28(2):187–196. https://doi.org/10.1016/j.smim.2016.03.018CrossRefPubMed

Pardee AD, Butterfield LH (2012) Immunotherapy of hepatocellular carcinoma: unique challenges and clinical opportunities. Oncoimmunology 1(1):48–55. https://doi.org/10.4161/onci.1.1.18344CrossRefPubMedPubMedCentral

Pasello G, Pavan A, Attili I et al (2020) Real world data in the era of immune checkpoint inhibitors (ICIs): increasing evidence and future applications in lung cancer. Cancer Treat Rev 87:102031. https://doi.org/10.1016/j.ctrv.2020.102031CrossRefPubMed

Reul J, Frisch J, Engeland CE et al (2019) Tumor-specific delivery of immune checkpoint inhibitors by engineered AAV vectors. Front Oncol 9:52. https://doi.org/10.3389/fonc.2019.00052CrossRefPubMedPubMedCentral

Rizzo A, Ricci AD, Brandi G (2021a) Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy. Future Oncol 17(7):755–757. https://doi.org/10.2217/fon-2020-0986CrossRefPubMed

Rizzo A, Ricci AD, Brandi G (2021b) Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait. Immunotherapy 13(8):637–644. https://doi.org/10.2217/imt-2021-0026CrossRefPubMed

Sacdalan DB, Lucero JA, Sacdalan DL (2018) Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. Onco Targets Ther 11:955–965. https://doi.org/10.2147/OTT.S153290CrossRefPubMedPubMedCentral

Salhab M, Canelo R (2011) An overview of evidence-based management of hepatocellular carcinoma: a meta-analysis. J Cancer Res Ther 7(4):463–475. https://doi.org/10.4103/0973-1482.92023CrossRefPubMed

Schachter J, Ribas A, Long GV et al (2017) Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 390(10105):1853–1862. https://doi.org/10.1016/S0140-6736(17)31601-XCrossRefPubMed

Shao YY, Liu TH, Hsu C et al (2019) Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma. Liver Int 39(11):2184–2189. https://doi.org/10.1111/liv.14210CrossRefPubMed

Shigeta K, Datta M, Hato T et al (2019) Duan programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma. Hepatology 71:1247–1261. https://doi.org/10.1002/hep.30889CrossRefPubMed

Simmons CE, Brezden-Masley C, McCarthy J, McLeod D, Joy AA (2020) Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer. Ther Adv Med Oncol 12:1758835920909091. https://doi.org/10.1177/1758835920909091CrossRefPubMedPubMedCentral

Tella SH, Mahipal A, Kommalapati A, Jin Z (2019) Evaluating the safety and efficacy of nivolumab in patients with advanced hepatocellular carcinoma: evidence to date. Onco Targets Ther 12:10335–10342. https://doi.org/10.2147/OTT.S214870CrossRefPubMedPubMedCentral

Tovoli F, De Lorenzo S, Trevisani F (2020) Immunotherapy with checkpoint inhibitors for hepatocellular carcinoma: where are we now? Vaccines (basel) 8(4):578. https://doi.org/10.3390/vaccines8040578CrossRef

Vitale A, Trevisani F, Farinati F, Cillo U (2020) Treatment of hepatocellular carcinoma in the precision medicine era: from treatment stage migration to therapeutic hierarchy. Hepatology. https://doi.org/10.1002/hep.31187CrossRefPubMed

Wang Y, Jiang M, Zhu J et al (2020) The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma. Biomed Pharmacother 132:110797. https://doi.org/10.1016/j.biopha.2020.110797CrossRefPubMed

Xu W, Liu K, Chen M et al (2019) Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives. Ther Adv Med Oncol 11:1758835919862692. https://doi.org/10.1177/1758835919862692CrossRefPubMedPubMedCentral

Yau T, Kang YK, Kim TY et al (2020) Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol 6(11):e204564. https://doi.org/10.1001/jamaoncol.2020.4564CrossRefPubMedPubMedCentral

Zeng Z, Yang B, Liao ZY (2020) Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma. Oncol Lett 20(4):45. https://doi.org/10.3892/ol.2020.11909CrossRefPubMedPubMedCentral

Zhu AX, Finn RS, Edeline J et al (2018) Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 19(7):940–952. https://doi.org/10.1016/S1470-2045(18)30351-6CrossRefPubMed

Title: The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals
Authors: Rixiong Wang
Nan Lin
Binbin Mao
Qing Wu
Publication date: 01-05-2022
Publisher: Springer Berlin Heidelberg
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Sorafenib
Checkpoint Inhibitors
Published in: Journal of Cancer Research and Clinical Oncology / Issue 5/2022
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-021-03716-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2022

Statistical recomendations for the authors of manuscripts submitted to the Journal of Cancer Research and Clinical Oncology

Complementary and alternative medicine (CAM) supplements in cancer outpatients: analyses of usage and of interaction risks with cancer treatment

Radiotherapy resistance: identifying universal biomarkers for various human cancers

Immunotherapy maintenance therapy for advanced urothelial carcinoma (aUC): a comprehensive review

The 3D in vivo chorioallantoic membrane model and its role in breast cancer research

Efficacy and safety of anti-PD-1 inhibitor combined with nab-paclitaxel in Chinese patients with refractory melanoma

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page